Clear Cell Renal Cell Carcinoma

P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center

P3, N=701, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Apr 2024 --> Jan 2026

P1/2, N=270, Recruiting, Debiopharm International SA | N=170 --> 270

CDKN2A and CDC20 expressions correlated significantly with stage and grade, while TGFB1, CDKN2A, and CDC20 were highly expressed in proliferative tumor cells. This study provides new biomarkers for KIRC, offering valuable insights into its developmental mechanisms for the research of CIC in this disease.

Taken together, these findings indicate that TRIP13 is associated with poor prognosis in eight human cancers and serves as a novel biomarker for predicting immunotherapy efficacy. Our first pan-cancer study contributes to personalized precision medicine in cancer immunotherapy, promoting subsequent clinical management and improving patient prognosis.

LPCAT3was identified as a ccRCC biomarker and may regulate immune infiltration and prognosis in ccRCC by mediating ferroptosis and ERS. Thus, it has potential for exploitation as a prognostic and immune therapeutic target for patients with ccRCC.

Our study presents a novel risk stratification method and prognostic model for ccRCC. And we identified the SPIB-SAA1-AKT pathway as one of the potential mechanisms by which AST factors promote ccRCC metastasis.

This case highlights the importance of thorough diagnostic evaluation in atypical presentations. The postoperative course was uneventful, and she subsequently received adjuvant therapy.

The integration of these imaging tools into clinical workflows enhances personalized treatment efficacy for CD70-expressing cancers. Radiotheranostic strategies can further allow the simultaneous diagnosis and treatment of malignancies, opening new horizons for the precise management of CD70+ tumors.

While 11 of 13 ELOC-RCCs were confined to the kidney, two ELOC-RCCs were high-stage and exhibited a large solid alveolar pattern, tumor necrosis, more SCNAs, and an additional monoallelic VHL copy loss. Taken together, ELOC-RCCs exhibit distinctive genomic features and indolent behavior in general, supporting it as an independent diagnostic entity.

Consequently, this cascade promoted RCC progression. In conclusion, our findings indicate that SAP30 inhibits the p53 pathway through MT1G suppression, suggesting that SAP30 and MT1G are potential prognostic markers and therapeutic targets for RCC.

These findings provide novel insights into the molecular heterogeneity of ccRCC and emphasize the interconnected roles of immune dysregulation and metabolic alterations in tumor progression. By identifying key prognostic biomarkers and potential therapeutic targets, this study paves the way for innovative strategies aimed at harnessing immune and metabolic pathways for better clinical outcomes in ccRCC patients.

We also show that downstream transcriptional changes induced by pRb hyperstabilization may contribute to ccRCC tumor development. Together, our findings reveal a novel VHL-related pathway which can be therapeutically targeted to inhibit ccRCC tumor development.

This study reveals that arsenic exposure induces pyroptosis via NLRP3, leading to renal injury and influencing the malignant progression of renal cancer. Notably, GPX4 and RPL40 regulate this progression under low and high-dose arsenic exposure, respectively.

SOX9, E-cadherin, and KLF4 expressions are linked to unfavourable prognostic factors in ccRCC. Thus, these immunohistochemical stains may serve as potential biomarkers in this cancer and aid in identifying prognosis and treatment response.

P1, N=67, Active, not recruiting, MedImmune LLC | Trial completion date: Aug 2027 --> Sep 2025 | Trial primary completion date: Aug 2027 --> Sep 2025

Protein Flexibility-Molecular Dynamic (MD) Simulation study indicated that mutations weaken the interaction of VHL with Elongin C, with V170F showing the most significant reduction in binding quality and stability. In conclusion, this study introduces novel genetic data from an understudied population and highlights the impact of VHL mutations on its interaction with Elongin C. These findings contribute to our understanding of the molecular basis of VHL-related pathologies and may guide future therapeutic strategies targeting these interactions.

We successfully validated epidermal growth factor receptor (EGFR) and piccolo presynaptic cytomatrix protein (PCLO), corroborated through independent datasets and biological experimentation. This approach may also be used for other diseases in the future.

P3, N=413, Recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: Jun 2025 --> Jun 2028 | Trial primary completion date: Dec 2024 --> Dec 2026

Given the low expression of DDX24, ccRCC patients may benefit more from immunotherapies. In conclusion, these findings demonstrate that DDX24 suppresses ccRCC progression through direct regulation of AKR1B10, potentially mediated by EMT-related pathways, which provides potential therapeutic targets for ccRCC.

P1, N=11, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | N=40 --> 11 | Trial completion date: Dec 2025 --> Aug 2024

Transcription factor enrichment analysis identified ELF3 as a regulator of invasive properties. Our integrative approach uncovered multiple roles for ANXA4 in modulating membrane repair, transcriptional regulation, and shaping the ccRCC tumor microenvironment composition.

P2, N=89, Recruiting, Rahul Aggarwal | Trial completion date: Sep 2027 --> Mar 2028 | Trial primary completion date: Sep 2027 --> Mar 2028

When rapidly growing cancer cells create a hypoxic environment, hyperactivated YAP1 in cancer cells induces the production of VEGF, which promotes the angiogenesis of tumor-associated endothelial cells, leading to improved tumor microenvironment and continuous tumor growth. Our study indicates that hyperactivated YAP1 is essential for maintaining ccRCC progression, and targeting the dual role of hyperactivated YAP1 represents a novel strategy to improve renal carcinoma therapy.

Genomic analysis revealed a correlation between low-CXCR5+CD8+ status and high rates of alterations in chromatin remodelling genes, including PBRM1. This study highlights the significance of CXCR5+CD8+ cells in ccRCC, demonstrating their clinical implications and revealing the immunogenomic landscape underlying CXCR5 expression.

PSMA showed high expression in metastases of ccRCC.

P1/2, N=130, Recruiting, Arsenal Biosciences, Inc. | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: Feb 2025 --> Mar 2026

P=N/A, N=40, Recruiting, The Affiliated Hospital of Qingdao University

The study highlights NAPSA's expression characteristics and potential role in ccRCC, suggesting it may serve as a biomarker. Further research is needed to elucidate NAPSA's mechanisms and explore its applications in precision medicine.

These study findings suggest that APOBEC3 genes are commonly overexpressed in ccRCC, and their expression levels are associated with poor prognosis in ccRCC, somatic gene mutations, cancer immunomodulation, and immune cell infiltration levels in the tumor microenvironment.

Our research shed light on the controversial and tumor-specific role of HSP70s. More in detail, we have identified HSPA8 and HSPA9 as potential prognostic and therapeutic targets involved in several biological processes leading to tumorigenesis, including nucleic acid maturation, cell signaling, vesicle trafficking, mitochondrial structure and function, and protein maturation.

Our study explored the mechanisms of DLX4 in pan-cancer, especially in renal clear cell carcinoma, identifying it as a promising biomarker and therapeutic target.

KIF14 down-regulates cell cycle proteins CyclinD1 and CDK4 to facilitate the proliferation of ccRCC cells, suggesting its potential as a therapeutic target and prognostic biomarker in ccRCC.

PD-1-positive TIIC score of TN and tumor necrosis may efficiently predict recurrence in pT1b ccRCC.

The FRGs model offers a novel approach for prognostic prediction of ccRCC patients and has the potential to provide personalized prognostic prediction and treatment for ccRCC patients.

Indeed, ccRCC lines lacking all three pRB family members remained at least partially HIF2a-dependent. In this context, however, a kinase-defective Cyclin D1 variant partially overrode belzutifan's antiproliferative effects, suggesting that ccRCC promotion by Cyclin D1 requires the phosphorylation of pRB paralogs and one or more kinase-independent Cyclin D1 activities.

Moreover, we identified a decrease in m6A levels in cancer samples. These findings might represent novel evidence to further investigate the issue, to reveal new diagnostic markers for tumorigenesis, leading to a potential m6A-targeted therapy in ccRCC.

This study reveals that GAMT has pro-oncogenic abilities in promoting ccRCC development and progression. GAMT exerted its non-enzymatic functions possibly by regulating the expression of p53. Fisetin, the novel GAMT inhibitor identified herein, may serve as a new antitumor drug for ccRCC treatment.

P1, N=1274, Active, not recruiting, Exelixis | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Jun 2030 | Trial primary completion date: Feb 2026 --> Jun 2030

P=N/A, N=1220, Recruiting, Hospital of Macerata | Trial completion date: Dec 2024 --> Sep 2027

In addition, it was found that the high and low risk groups had different sensitivities to the drugs Etoposide, Imatinib, Sorafenib, Bosutinib and Sunitinib. A novel prognostic model was constructed based on four DElncRNAs-related to DDR. The model has satisfactory accuracy in predicting survival of ccRCC patients.

The hub SF MBNL1 identied in the present study could inhibit the progression of ccRCC. This effect is likely due to the regulation of QKI expression through AS.